Anthony Fauci ” “More than 90 per cent, close to 95 per cent,” on the Pfizer vaccine
Pfizer AND BIONTECH announced a very positive update to their upcoming COVID-19 vaccine. Pfizer mRNA vaccine candidate, BNT162b2 is more than 90% effective in preventing COVID-19 among people with no prior evidence of SARS-CoV-2 infection. The study enrolled 43,538 participants and evaluated 94 confirmed cases of the novel coronavirus among the trial participants. The study did not encounter any serious adverse effects of administrating the vaccine among the participants. The first interim analysis in the global phase 3 study is a significant achievement based on the evidence provided during the study. The Monday morning news caused a 7.69% spike in the Pfizer stock price over the Friday evening closing price. Pfizer had a closing market capitalization of $214.665B and trading at a PE (TTM) of 25.11 at the closing price on 13 November.
The COVID-19 vaccine was tested among a very diverse and ethnically diverse set of people Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. The first interim analysis (which employed randomized control trial) minimum of 62 cases split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, 7 days after the second dose. PFIZER AND BIONTECH can produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021 based on current projections. Pfizer looks as the best bet against the novel coronavirus at present (along with AstraZeneca) and can hit the US as early as December. The announcement of the vaccine can be a gamechanger for Americans as the second wave of COVID-19 causes havoc worldwide. If the vaccine truly lives up to its potential, the impact evaluation is astronomical. Serum Institute of India can deliver 100 million doses of the AstraZeneca vaccine in India by December depending on the success of final stage trial.
The US which is already reeling under the pandemic has seen ~ 120871 average new daily cases between 1 November and 14 November based on the data provided by the European Centre for Disease Prevention & Control. As cases spread across Europe, France has extended the lockdown until December 1, 2020. With total cases shooting past 11 million in the US followed by India is closing on the 9 million mark, vaccination looks like the only savior for a long-lasting solution to the pandemic. As the pandemic causes both social and financial upheaval, the next couple of months remain crucial. Moderna, another leading vaccination candidate has completed enrollment of its Phase 3 COVE study of mRNA-1273 on October 22.
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced on 11 November its interim analysis of its COVID-19 vaccine. The company is accelerating its vaccine initiation in Switzerland by including the rolling submission of mRNA-1273 data to cut down the time taken for authorization for the vaccine.
Despite the positive news, as infections growing at an alarming exponential rate, hope floats.